L3VLUP
ProSign in

MDT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMDTJNJ
Q3 202032 holders, $18.3bn30 holders, $26.2bn
Q4 202033 holders, $20.0bn32 holders, $26.6bn
Q1 202137 holders, $20.8bn31 holders, $25.3bn
Q2 202134 holders, $22.1bn37 holders, $25.6bn
Q3 202132 holders, $21.6bn40 holders, $24.1bn
Q4 202131 holders, $18.5bn33 holders, $25.2bn
Q1 202228 holders, $18.0bn35 holders, $28.2bn
Q2 202235 holders, $15.2bn33 holders, $26.9bn
Q3 202233 holders, $13.7bn36 holders, $25.4bn
Q4 202232 holders, $13.4bn35 holders, $27.6bn
Q1 202325 holders, $13.6bn42 holders, $24.5bn
Q2 202330 holders, $15.2bn38 holders, $25.0bn
Q3 202328 holders, $13.1bn37 holders, $18.9bn
Q4 202324 holders, $12.7bn31 holders, $19.0bn
Q1 202419 holders, $12.8bn32 holders, $19.7bn
Q2 202426 holders, $11.2bn35 holders, $20.4bn
Q3 202430 holders, $13.9bn28 holders, $22.3bn
Q4 202433 holders, $11.5bn37 holders, $20.4bn
Q1 202527 holders, $13.8bn32 holders, $20.5bn
Q2 202530 holders, $13.3bn31 holders, $18.4bn
Q3 202525 holders, $13.6bn32 holders, $23.7bn
Q4 202527 holders, $14.9bn29 holders, $27.8bn
Q1 202624 holders, $14.3bn34 holders, $35.6bn
Q2 202629 holders, $12.8bn33 holders, $39.1bn
MDT

Medtronic PLC

Holders
33
Reported value
$11.5bn
Buyers
19
Sellers
15

Breadth +4 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDT (7)

Artisan Partners LP, Baillie Gifford & Co, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Polen Capital Management LLC, Tudor Investment Corp, Two Sigma Investments LP

Only JNJ (11)

Balyasny Asset Management LLC, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Markel Group Inc, Susquehanna International Group LLP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →